Sienna Biopharmaceuticals Inc
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical … Read more
Sienna Biopharmaceuticals Inc (SNNAQ) - Total Assets
Latest total assets as of September 2019: $43.49 Million USD
Based on the latest financial reports, Sienna Biopharmaceuticals Inc (SNNAQ) holds total assets worth $43.49 Million USD as of September 2019.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sienna Biopharmaceuticals Inc - Total Assets Trend (2015–2018)
This chart illustrates how Sienna Biopharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sienna Biopharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2018)
Sienna Biopharmaceuticals Inc's total assets of $43.49 Million consist of 47.0% current assets and 53.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $311.00K | 0.3% |
| Intangible Assets | $45.59 Million | 42.5% |
| Goodwill | $10.99 Million | 10.2% |
Asset Composition Trend (2015–2018)
This chart illustrates how Sienna Biopharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sienna Biopharmaceuticals Inc's current assets represent 47.0% of total assets in 2018, a decrease from 98.0% in 2015.
- Cash Position: Cash and equivalents constituted 45.2% of total assets in 2018, down from 86.2% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 52.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 42.5% of total assets.
Sienna Biopharmaceuticals Inc Competitors by Total Assets
Key competitors of Sienna Biopharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Sienna Biopharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Sienna Biopharmaceuticals Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Sienna Biopharmaceuticals Inc is currently not profitable relative to its asset base.
Sienna Biopharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.27 | 4.86 | 1.06 |
| Quick Ratio | 15.27 | 4.86 | 1.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $18.44 Million | $ 53.25 Million | $ 640.00K |
Sienna Biopharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Sienna Biopharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -21.6% |
| Total Assets | $107.31 Million |
| Market Capitalization | $3.08K USD |
Valuation Analysis
Below Book Valuation: The market values Sienna Biopharmaceuticals Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sienna Biopharmaceuticals Inc's assets decreased by 21.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sienna Biopharmaceuticals Inc (2015–2018)
The table below shows the annual total assets of Sienna Biopharmaceuticals Inc from 2015 to 2018.
| Year | Total Assets | Change |
|---|---|---|
| 2018-12-31 | $107.31 Million | -21.59% |
| 2017-12-31 | $136.85 Million | +119.39% |
| 2016-12-31 | $62.38 Million | +984.06% |
| 2015-12-31 | $5.75 Million | -- |